Our research revolves around key algorithmic and statistical challenges that arise in computational biology, with a particular focus on variant effect prediction and single-cell genomics — and is highly collaborative, spanning multiple biological domains in immunology, human genetics, and cancer biology.
Dr. Olshen has helped develop tools in such area as DNA copy number, mutation hotspot detection, and integration of data from multiple genomic assays. He is currently developing biomarkers to predict cancer outcomes in pediatric cancers.
Dr. Fragiadakis’s research focuses on analyzing immune state in diverse sets of patient cohorts using high-dimensional single-cell technologies, including single-cell sequencing and CyTOF. She uses multi-modal data integration methods to evaluate patient differences and infer broader principles of immune organization.
The main theme of our research is large-scale analysis of disease genomes by integrating multi-omics data, evolutionary insights, electronic health records, as well as digitized clinical traits from imaging and wearable sensor readouts. The ultimate goal is to build data-driven frameworks to detect diseases before symptoms emerge and to achieve precision health management.
Ramani Lab invents molecular tools to study biology, e.g. devising ways to molecularly tag nucleic acids and proteins with unique genomic or proteomic identifiers, then using these to quantify biological phenomena at the level of single cells and single molecules, using high-throughput sequencing and cutting-edge mass spectrometric techniques.
Dr. Goldstien uses the tools of big data, statistics and machine learning to answer questions related to Precision Medicine such as: How can we learn from the inventory of genomic test and knowledge in the EMR about patient outcomes and the data associated with individual patients to better direct their care? How can we better use repeatable animal models to translate knowledge to human patients? How can we integrate existing knowledge and high throughput data? Can we use genomic data to bring new therapies to bear?
The Zaitlen lab develops statistical and computational tools to discover the genetic basis of complex phenotypes, with particular interest in human disease, variation in drug/treatment response, and disease outcomes. Current projects primarily focus on incorporating environmental context into medical genetics.
Dr. van ‘t Veer’s research focuses on personalized medicine, to advance patient management based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. This allows clinicians to optimally assign systemic therapy for those patients in need of such treatment, and to ensure the selection of the therapy that is most effective.
The Goodarzi laboratory employs a systems biological and multidisciplinary approach that integrates computational and experimental strategies to identify and characterize key regulatory programs that underlie cancer progression.
Dr Baranzini’s current research involves immunological studies using the EAE model, sequencing of whole genomes and transcriptomes from patients with multiple sclerosis and developing bioinformatics tools to integrate this information with that coming from other high throughput technologies. Dr Baranzini uses a combination of “wet lab” methods including DNA microarrays, proteomics, and laser capture microdissection, in combination with “dry lab” analytical approaches encompassing bioinformatics, complexity theory, and mathematical modeling.
The lab seeks to discover new therapeutic approaches to target the genetic mutations and altered signaling networks that are specific to cancer cells. Using functional genomics applied to mouse and human systems, we work to understand the transcriptional networks that regulate the outcome of specific oncogenic mutations and to understand how cancers become resistant to chemotherapy. This work relies heavily on computational genomic analysis, generating and using high-throughput datasets and next-generation sequencing for gene and network discovery. Our primary disease focus is lung cancer and pediatric sarcomas.
Dr. Kober uses ‘omics data (i.e., genotype and expression arrays, DNAseq — genome, exome, RNAseq, methylation arrays) to improve our understanding of the molecular mechanisms underlying common symptoms (e.g., fatigue, pain) or treatment failure experienced by patients with chronic medical conditions (e.g., cancer, HIV infection).
Dr. Segal has devised methods for addressing several aspects of analyzing data deriving from high-throughput biotechnologies, straddling low-level (e.g., pre-processing) to high-level (e.g., linked survival phenotypes, regulatory module elicitation) approaches. He is currently engaged in developing and comparing methods for inferring 3D genome architecture utilizing data from chromatin conformation capture assays.
Dr. Pollard’s group aims to identify specific DNA alterations that are responsible for novel functionality, such as variation in gene expression.
This collaborative team of data scientists, computational biologists and genome detectives, have a shared vision —a fundamental understanding of human biology with an eye to improving human health. See website
The Butte lab builds tools in translational bioinformatics to make sense of big ‘omics and clinical data and solve new classes of problems in Oncology.
